Caplin Point Laboratories Announcements
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA for the Potassium Phosphates Injection USP
13 Mar, 2026 | 11:52am • Source: BSE
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for the Desmopressin Acetate Injection USP
28 Feb, 2026 | 11:45am • Source: BSE
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Sodium Phosphates Injection USP
24 Feb, 2026 | 12:17pm • Source: BSE
Investor Presentation for the quarter and nine months ended December 31, 2025
05 Feb, 2026 | 02:22pm • Source: BSE
Unaudited standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2025
05 Feb, 2026 | 01:22pm • Source: BSE
Outcome of the Board Meeting held on February 05, 2026
05 Feb, 2026 | 01:08pm • Source: BSE
Appointment of Directors of the Company
03 Feb, 2026 | 03:23pm • Source: BSE
Voting results and Scrutinizer report for the Postal Ballot dated January 31, 2026
03 Feb, 2026 | 02:55pm • Source: BSE
Analyst / investor Call for the quarter ended December 31, 2025
29 Jan, 2026 | 03:54pm • Source: BSE
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the ANDA Methylprednisolone Acetate Injectable Suspension USP.
27 Jan, 2026 | 03:28pm • Source: BSE
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider...
27 Jan, 2026 | 11:37am • Source: BSE
Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
14 Jan, 2026 | 11:28am • Source: NSE
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025
14 Jan, 2026 | 11:23am • Source: BSE
Company had disseminated a press release containing information on acquisition of ten ANDAs from a Global generic manufacturing company.
01 Jan, 2026 | 11:44am • Source: BSE
Intimation of Closure of Trading window commencing from January 01, 2026.
31 Dec, 2025 | 06:31pm • Source: BSE
We enclose herewith the Notice of Postal Ballot of Caplin Point Laboratories Limited seeking the approval of members for the resolutions mentioned in the Notice.
31 Dec, 2025 | 03:24pm • Source: BSE
Press Release on the company''s Subsidiary, Caplin Steriles Limited, getting USFDA approval for its ANDA Linezolid Injection 600 mg/ 300 mL (2 mg/mL) Single Dose...
09 Dec, 2025 | 01:57pm • Source: BSE
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited from USFDA for ANDA Acetaminophen Injection, 1000 mg/100 mL (10 mg/ mL)...
08 Dec, 2025 | 03:36pm • Source: BSE
Acquisition of land by Subsidiary at Mexico
14 Nov, 2025 | 05:19pm • Source: BSE
Transcript of the Earnings Call - Q2 & H1 FY 2025-26
12 Nov, 2025 | 06:49pm • Source: BSE